Publications by authors named "A Mortezavi"
Article Synopsis
- The study investigated the impact of statin use on prostate cancer (PCa) development and prostate-specific antigen (PSA) levels in a cohort of 4,314 men over nearly 10 years.
- Statin users (761 men) had significantly lower baseline and follow-up PSA levels compared to non-users, but the overall incidence of PCa was similar between the two groups, indicating statins did not reduce the risk of developing PCa.
- Additionally, statin users had a higher risk of overall mortality, suggesting that while they had lower PSA levels, statin use did not confer a protective effect against prostate cancer.
ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian framework to evaluate efficacy within predefined biomarker signatures across systemic treatments. Prospective circulating tumor DNA and germline DNA analysis was performed in patients with metastatic castration-resistant prostate cancer before randomization to androgen receptor pathway inhibitors (ARPIs), taxanes or a physician's choice control arm. The primary endpoint was the time to no longer clinically benefitting (NLCB).
View Article and Find Full Text PDFBackground: Magnetic resonance imaging (MRI) followed by targeted biopsy (TBx) is utilized for prostate cancer (PCa) detection. However, the value of adding systematic biopsies (SBx) to targeted biopsy procedures (combined biopsy; CBx) in men with suspicious MRI findings has not been determined.
Methods: We analysed biopsy outcomes in 429 men with MRI lesions in the prospective multicenter STHLM3MRI pilot study, planned for prostate biopsy.
Background And Objective: Building on previous research demonstrating better prostate cancer (PC) diagnostics via a biomarker-enhanced approach, this study focuses on cost analysis of PC care using the Stockholm3 test. We assessed the economic impact in European health care systems using real-world evidence for diagnostic outcomes and relevant costs.
Methods: We evaluated two PC diagnostic strategies: (1) the conventional prostate-specific antigen (PSA) strategy with magnetic resonance imaging (MRI) and (2) PSA testing with a reflex to biomarkers at PSA ≥1.